Peptide library

TB-500

In FDA and HHS documents, TB-500 is a synthetic seven-amino-acid fragment of thymosin β4. What has been studied, in which models, what regulators said about safety, and where it stands in November 2026.

Short answerCompound research · 6 min read · Updated 18 Nov 2026

TB-500 is the name FDA and HHS documents give to Ac-LKKTETQ, a synthetic seven-amino-acid fragment of the human protein thymosin β4. Its research is in animals and cells; no controlled human study has been published, and one placebo-controlled trial is recruiting. It is not an approved medicine, and WADA prohibits it at all times.

Key takeaways

  • In FDA and HHS documents, TB-500 is Ac-LKKTETQ, a synthetic copy of positions 17 to 23 of thymosin β4; FDA staff say the two are not the same substance.
  • Its research is animal and cell work, and the 2003 mouse study used an unacetylated version that FDA staff say cannot be directly extrapolated to TB-500.
  • No controlled human study has been published; one placebo-controlled trial began recruiting in February 2026.
  • FDA says it lacks the information to know whether TB-500 would cause harm in people; HHS called FDA staff’s concerns inferential rather than observed.
  • WADA prohibits it at all times under S2.3, and Australia lists it in Schedule 4 of the Poisons Standard.

01TB-500 at a glance

The short version, dated 18 November 2026.

QuestionTB-500
What it isA synthetic, N-acetylated seven-amino-acid peptide, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), matching positions 17 to 23 of the 43-amino-acid protein thymosin β4. Molecular weight 889.01 g/mol as the free peptide.
Other namesThymosin β4 fragment 17–23. FDA’s compounding page lists it as “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500”. FDA staff write that thymosin β4 and TB-500 “are not the same substance”.
Evidence tierT3 (animal) and T4 (cell). In people: one uncontrolled report of three patients given several agents at once (T2).
Human studiesNo controlled human study published (PubMed, 18 Nov 2026). One registered trial: phase 1/2, randomised, placebo-controlled, estimated n=80, recruiting, no results.
United StatesNot FDA-approved. In FDA’s compounding Category 2 from 29 Sep 2023 to 22 Apr 2026, now listed as a nomination withdrawn. Named in HHS’s draft enforcement-discretion policy for licensed compounders (Federal Register notice, 30 Oct 2026), which is not binding and not an approval.
United KingdomFDA’s 2026 briefing reports no approved product containing TB-500 in the UK.
AustraliaSchedule 4 (prescription only) and Appendix D, clause 5, of the Poisons Standard October 2026, in force from 1 Oct 2026.
WADAProhibited at all times, class S2.3: “Thymosin-β4 and its derivatives e.g. TB-500” (2026 List; the 2027 List keeps the entry).

02What is TB-500, and why does the name confuse people?

FDA’s 2026 review describes TB-500 as a synthetic, N-acetylated copy of positions 17 to 23 of thymosin β4, a stretch that contains the protein’s actin-binding region. HHS’s policy appendix gives the same sequence, Ac-LKKTETQ. Thymosin β4 is a 43-amino-acid protein made by many cell types and found in blood, saliva, tears and wound fluid. It binds single units of actin, the protein that cells link into the filaments they use to hold their shape and move.

FDA staff write that the fragment appears to have first been made for a 2003 mouse study, and that a veterinary preparation was marketed for equine and greyhound sports from 2011.

What a vial sold under the name contains is a separate question, and only that lot’s lab report answers it. The fragment is 7 amino acids long and the protein 43, so a mass spectrum tells them apart: see mass spectrometry explained. The side-by-side comparison is on TB-500 vs thymosin beta-4.

03How has TB-500 been studied, and in what models?

Almost everything published is animal or cell work, and the best-known animal study did not use TB-500 itself.

Aged mice, 2003 (T3). In a study summarised by FDA staff, researchers made small skin wounds on 26-month-old mice and applied either the full protein or the seven-amino-acid peptide LKKTETQ without the acetyl group. At day 7, tissue samples suggested more closure of the skin surface and more collagen with both. FDA staff note that acetylation can change a peptide’s lifespan, folding and binding, so these results “cannot be directly extrapolated” to TB-500.

Cells, 2024 (T4). In a scratch test on cultured fibroblasts, also summarised by FDA staff, closure of the scratch with TB-500 did not differ significantly from the control solution, while one of its breakdown products caused a small, significant change. That is not evidence about people.

Rats, 2026 (T3). A study from Istanbul cut and repaired the Achilles tendon in 32 rats, eight per group. Its material is described as “synthetic thymosin beta-4 (TB-500)”, and the abstract does not say whether that was the fragment or the full protein. After four weeks, the TB-500 group had a higher load to failure and lower degeneration scores than controls given no peptide, and adding BPC-157 gave no extra benefit over either peptide alone. Human data on this is lacking.

People (T2, uncontrolled). FDA staff found no articles in which TB-500 was given to humans. A 2026 report then described three dental patients with nerve injury who received TB-500 together with BPC-157, ARA-290, dexamethasone and a local anaesthetic. With no control group, its authors write that causality “cannot be established”.

The first trial (registered). NCT07487363 is a randomised, placebo-controlled phase 1/2 study planned for 80 adults with stable atherosclerotic cardiovascular disease, in three sequential cohorts, with adverse events as its primary outcome. It began in February 2026 and is recruiting, with no results. Trials of the full protein are a separate body of evidence and did not test TB-500: see the comparison.

04What have regulators said about TB-500 safety?

There is no controlled human safety data on TB-500, only regulators’ reasoning and a few reports, which do not all point the same way.

FDA. FDA’s compounding page says products containing the fragment “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities”, that FDA “has not identified any human exposure data”, and that it lacks information on “whether it would cause harm if administered to humans”. Its staff concluded that “potential safety risks associated with the use of these substances in humans are unknown”.

Adverse-event reports. FDA’s search of FAERS, its adverse-event database, found no TB-500 reports through 26 March 2025. Its foods and cosmetics complaint system held two cases about “blended TB-500 and BPC-157”, without safety assessments. FDA’s separate BPC-157 review describes a woman who used a product labelled for research purposes containing BPC-157 and TB-500 and developed darkening of the skin and gums that returned when she used it again. FDA staff judged the reactions “likely due to the drug product”; because it contained two peptides, they could not assess whether BPC-157 played a role.

HHS. HHS’s 2026 policy appendix calls the safety concerns FDA staff identified “inferential rather than observed”, says the parent protein has “a controlled human safety record across several routes”, and says the fragment is “rapidly truncated in human serum”.

None of these sources is a controlled study of TB-500 in people. How to read reports like these: side effects, documented vs unknown.

05Is TB-500 an approved medicine? Status by country

United States. TB-500 is not an FDA-approved drug. HHS records that it sat in FDA’s compounding Category 2 from 29 September 2023 to 22 April 2026, that neither the placement nor the removal changed its status under section 503A, and that FDA’s compounding advisory committee voted in favour of listing it after FDA staff recommended against. HHS then named TB-500 among six peptides in a policy saying it does not intend to pursue enforcement against state-licensed pharmacies, federal facilities and licensed physicians compounding with them, under conditions that include a patient-specific prescription. The Federal Register notice of 30 October 2026 calls the policy a draft that “is not binding”. It is not an approval. Background: the July 2026 committee vote and the HHS policy.

United Kingdom. FDA’s 2026 briefing reports no approved product containing TB-500 in the UK, Australia, Canada or seven other European countries, and none authorised by the European Medicines Agency. How UK medicines law treats peptides: are peptides legal in the UK?

Australia. The Poisons Standard October 2026 lists TB-500, and thymosin β4 as a separate entry, in Schedule 4 (prescription only) and in Appendix D, clause 5, “poisons for which possession without authority is illegal”. More: are peptides legal in Australia?

Sport. WADA’s 2026 Prohibited List names “Thymosin-β4 and its derivatives e.g. TB-500” in class S2.3, growth factors and growth factor modulators, prohibited at all times. The 2027 List, in force from 1 January 2027, keeps the entry. See peptides and anti-doping.

06What doesn’t TB-500 research show?

  • Any effect of TB-500 in people from a controlled study. None has been published, and the first registered trial has not reported.
  • That results with the unacetylated peptide or the full protein apply to TB-500. FDA staff say they cannot be directly extrapolated.
  • How TB-500 behaves in the human body, or its long-term safety. FDA staff found no human pharmacokinetic or safety data.
  • What a given vial sold as TB-500 contains. Only that lot’s lab report can show it: how to read a COA.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: TB-500-related bulk drug substances. Advisory committee briefing, 2026 (pp. 16–34). www.fda.gov/media/193349/download
  2. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  3. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026 (pp. 27, 40–43, 54–55). www.fda.gov/media/193343/download
  4. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, 2026. hhs.gov returned 403 to our fetch on 18 Nov 2026; read on the Internet Archive capture of 15 Nov 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  5. Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026; text read on govinfo 18 Nov 2026. www.federalregister.gov/documents/2026/10/30/2026-22192/enfo…
  6. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327), Schedule 4 and Appendix D. Federal Register of Legislation, registered 30 Sep 2026, commenced 1 Oct 2026; read 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  7. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027). International Standard; both PDFs read 18 Nov 2026. www.wada-ama.org/en/prohibited-list
  8. ClinicalTrials.gov. NCT07487363: phase 1/2, randomised, placebo-controlled study of TB-500 (thymosin beta 4 17–23 fragment) in adults with stable atherosclerotic cardiovascular disease. Registry record, last updated 12 Nov 2026; read 18 Nov 2026. clinicaltrials.gov/study/NCT07487363
  9. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg, 2026;37(3):822–837. PMID 42542926. pubmed.ncbi.nlm.nih.gov/42542926/
  10. Froum S, Estrin N, Pico G, et al. Case report: regenerative peptides for inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 2026;7:1907109. PMID 42876687. pubmed.ncbi.nlm.nih.gov/42876687/

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is TB-500 the same as thymosin beta-4?

No. In FDA and HHS documents, TB-500 is a synthetic seven-amino-acid fragment of the 43-amino-acid protein, with an acetyl group added. FDA staff write that the two are not the same substance.

Has TB-500 been tested in humans?

Not in a published controlled study. A 2026 report described three patients given TB-500 alongside several other agents, with no control group, and a placebo-controlled phase 1/2 trial began recruiting in February 2026 with no results yet.

Is TB-500 FDA-approved?

No. It came off FDA’s compounding Category 2 list in April 2026, after its nomination was withdrawn, and HHS later named it in a draft compounding enforcement-discretion policy. Neither step is an approval.

Is TB-500 prohibited in sport?

Yes. WADA lists “Thymosin-β4 and its derivatives e.g. TB-500” in class S2.3, prohibited in and out of competition, in both the 2026 and 2027 Lists.

What is TB-500’s status in Australia?

The Poisons Standard October 2026 lists TB-500 in Schedule 4, prescription only, and in Appendix D, clause 5, which covers poisons that may not be possessed without authority.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page